Literature DB >> 21996517

Molecular dynamics simulations and MM/GBSA methods to investigate binding mechanisms of aminomethylpyrimidine inhibitors with DPP-IV.

Liang Desheng1, Gao Jian, Cheng Yuanhua, Cui Wei, Zhang Huai, Ji Mingjuan.   

Abstract

The aminomethylpyrimidines were investigated as a novel class of DPP-IV inhibitors. In this Letter, the binding mechanisms of how slight change of substitution or position influences the binding affinity of five representative analogs was investigated by molecular dynamics simulation, free energy calculations and energy decomposition analysis. The conserved hydrogen bonds with Glu205 and Glu206 slightly favor the inhibitor binding; the van der Waals interactions, especially the two key contacts with Tyr547 and Tyr666, dominate in the binding free energy and play a crucial role on distinguishing the high active inhibitors from the low ones.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21996517     DOI: 10.1016/j.bmcl.2011.09.093

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  3 in total

1.  Molecular dynamic simulations reveal the mechanism of binding between xanthine inhibitors and DPP-4.

Authors:  Yongliang Gu; Wei Wang; Xiaolei Zhu; Keke Dong
Journal:  J Mol Model       Date:  2014-01-31       Impact factor: 1.810

2.  Ligand-Based Pharmacophore Modeling, Molecular Docking, and Molecular Dynamic Studies of Dual Tyrosine Kinase Inhibitor of EGFR and VEGFR2.

Authors:  Frangky Sangande; Elin Julianti; Daryono Hadi Tjahjono
Journal:  Int J Mol Sci       Date:  2020-10-21       Impact factor: 5.923

3.  A Search for Cyclin-Dependent Kinase 4/6 Inhibitors by Pharmacophore-Based Virtual Screening, Molecular Docking, and Molecular Dynamic Simulations.

Authors:  Ni Made Pitri Susanti; Sophi Damayanti; Rahmana Emran Kartasasmita; Daryono Hadi Tjahjono
Journal:  Int J Mol Sci       Date:  2021-12-14       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.